FDA posts favorable comments on NPS Pharmaceuticals' drug

The Food and Drug Administration posted briefing materials for NPS Pharmaceuticals Inc.'s (Nasdaq: NPSP) hormone replacement therapy Natpara indicating that the drug was effective. The stock price leaped $6.47 to close at $32.24.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.